Skip to main content
Explore URMC
menu

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Research Question:
Does the drug blinatumomab treat patients with relapsed B-cell acute lymphoblastic leukemia?

Basic Study Information

Purpose:
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Monoclonal antibodies, such as blinatumomab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.

Location: University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher: Angela Girvin

Study Contact Information

Study Coordinator: Site Public Contact
Phone: (585) 275-5830

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search